arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Immunome, Inc.

IMNM Health Care Biotechnology: Pharmaceutical Preparations
$18.26
▲ +1.9% Today
as of Oct 22, 16:49 ET
Last 30 days -25.62% Sep 14 → Oct 22
$15.73 $18.42 $21.11 $23.80 $26.49 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$17.78
High
$18.30
Low
$17.59
Volume
$2M
Avg Vol
$1M
Mkt Cap
$2.3B
P/E (TTM)
—
Beta
—
52w High
$30.06
52w Low
$14.64
Div Yield
—
Shares Out
$113M

Recent Press Releases & News last 60 days · 10 items

Oct 16 · 11:53 MT Newswires
William Blair Initiates Coverage on Immunome With Outperform Rating
Oct 13 · 22:16 Simply Wall St.
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus
Oct 6 · 20:02 PR Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
▸ Show all 10 press releases & news Free account →

IMNM earnings at a glance

Immunome, Inc. (IMNM) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of -$0.65, compared with -$0.65 in the same quarter last year (+0%). The options market is pricing a move of about ±12.0% after the report, a range of roughly $16.07 to $20.45 from today's $18.26. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±3.5% on average; after the most recent report on Aug 12, 2026 it moved +6.6%. That means options currently expect more movement than IMNM has typically delivered. IMNM beat the consensus EPS estimate in 3 of its last 6 reported quarters. Implied volatility is currently 72%. The share price of $18.26 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$15
$30
23% of range
Avg surprise (last 6)
-2.0%
Avg reaction (last 6)
+0.2%
33% positive
Latest IV / EM
72%
EM ±12.0% · $22 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.51$-1.97$-1.43$-0.89$-0.35 Actual $-0.35Actual $-0.46Actual $-0.36Actual $-2.51Actual $-0.60Actual $-0.78Actual $-0.52Est $-0.66Actual $-0.50Est $-0.52Actual $-0.65Est $-0.57Actual $-0.75Est $-0.65Actual $-0.48Est $-0.60Actual $-0.65Est $-0.51 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-73M$-54M$-34M$-15M$4M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed Aug 12, 2026Jun/2026 $-0.65 $-0.51 -27.4% -2.0% +6.6% earnings
Tue May 12, 2026Mar/2026 $-0.48 $-0.60 +20.0% +7.7% -2.2% earnings
Tue Mar 3, 20268K 2026-03-03 $-0.75 $-0.65 -15.4% — +4.5% earnings
Thu Nov 6, 2025Sep/2025 $-0.65 $-0.57 -14.0% — -1.7% earnings
Wed Aug 6, 2025Jun/2025 $-0.50 $-0.52 +3.9% — -5.6% earnings
Mon May 12, 2025Mar/2025 $-0.52 $-0.66 +21.2% — -0.4% earnings
Mon Sep 30, 2024Sep 2024 $-0.78 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.60 — — — — financials
Sun Mar 31, 2024Mar 2024 $-2.51 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.36 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.46 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.35 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$0.65-$0.65 0.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0$0—$0$4M$3M—$3M
Cost of revenue————————
Gross profit————————
Operating income$-78M$-59M—$-60M$-46M$-45M—$-51M
Net income$-73M$-54M—$-57M$-43M$-42M—$-47M
EPS (diluted)$-0.65$-0.48—$-0.65$-0.50$-0.52—$-0.78

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$218M$583M$653M$273M$144M$258M$143M$156M
Inventory————————
Total current assets$538M$594M$661M$280M$277M$323M$221M$244M
Total assets$565M$620M$683M$299M$296M$343M$240M$257M
Long-term debt————————
Total liabilities$40M$31M$49M$35M$27M$36M$59M$42M
Total equity$525M$589M$634M$264M$269M$307M$181M$215M

Implied volatility — last 90 days

47%105%162%220%278% Jun 07 — IV 103% · EM ±14.3%Jun 08 — IV 108% · EM ±14.2%Jun 09 — IV 217% · EM ±27.2%Jun 11 — IV 279% · EM ±30.8%Jun 12 — IV 266% · EM ±27.2%Jun 19 — IV 126% · EM ±27.7%Jun 22 — IV 109% · EM ±22.7%Jun 23 — IV 94% · EM ±19.3%Jun 24 — IV 129% · EM ±25.8%Jun 25 — IV 88% · EM ±17.3%Jun 26 — IV 154% · EM ±29.6%Jun 29 — IV 134% · EM ±23.8%Jun 30 — IV 97% · EM ±16.6%Jul 01 — IV 85% · EM ±14.2%Jul 02 — IV 111% · EM ±17.9%Jul 03 — IV 115% · EM ±17.9%Jul 07 — IV 68% · EM ±9.0%Jul 20 — IV 75% · EM ±17.7%Jul 21 — IV 108% · EM ±25.1%Jul 22 — IV 74% · EM ±16.8%Jul 23 — IV 101% · EM ±22.7%Jul 27 — IV 80% · EM ±16.7%Jul 28 — IV 117% · EM ±23.9%Jul 30 — IV 111% · EM ±21.8%Jul 31 — IV 115% · EM ±22.0%Aug 03 — IV 123% · EM ±21.7%Aug 04 — IV 126% · EM ±21.6%Aug 05 — IV 83% · EM ±13.9%Aug 06 — IV 67% · EM ±10.8%Aug 07 — IV 74% · EM ±11.6%Aug 10 — IV 117% · EM ±16.2%Aug 12 — IV 153% · EM ±19.1%Aug 13 — IV 77% · EM ±9.1%Aug 14 — IV 86% · EM ±9.5%Aug 17 — IV 229% · EM ±19.2%Aug 19 — IV 48% · EM ±2.8%Aug 24 — IV 83% · EM ±17.3%Aug 25 — IV 49% · EM ±10.1%Aug 26 — IV 74% · EM ±14.9%Aug 27 — IV 90% · EM ±17.7%Aug 28 — IV 53% · EM ±10.1%Aug 31 — IV 47% · EM ±8.4%Sep 09 — IV 49% · EM ±6.1%Sep 10 — IV 54% · EM ±6.4%Sep 14 — IV 90% · EM ±7.5%Sep 15 — IV 104% · EM ±7.5%Sep 21 — IV 89% · EM ±18.6%Sep 22 — IV 105% · EM ±21.6%Sep 23 — IV 114% · EM ±22.8%Sep 24 — IV 90% · EM ±17.6%Sep 25 — IV 82% · EM ±15.6%Sep 28 — IV 136% · EM ±24.1%Sep 29 — IV 70% · EM ±12.1%Sep 30 — IV 72% · EM ±12.0%

Sector peers

PBH
Prestige Consumer Healthcare Inc.
$2.3B $49.46+0.2%
HRMY
Harmony Biosciences Holdings, Inc.
$2.3B $36.03-6.9%
BHC
Bausch Health Companies Inc.
$2.3B $6.49+1.1%
LQDA
Liquidia Corporation
$2.4B $39.69+9.2%
KLRA
Kailera Therapeutics, Inc.
$2.4B $13.27+3.0%
TRVI
Trevi Therapeutics, Inc.
$2.0B $12.94+0.9%

IMNM earnings FAQ

When is IMNM's next earnings date?

Immunome, Inc. is expected to report on November 5, 2026.

What is IMNM's expected move for earnings?

Options currently price a move of about ±12.0%, or $2.19 per share either way from $18.26.

How does IMNM stock usually react to earnings?

Across the last 6 reports the average next-day move was ±3.5%, up 2 times and down 4 times.

What EPS are analysts expecting from Immunome, Inc.?

The consensus estimate is -$0.65 per share, versus -$0.65 a year ago.

What is IMNM's implied volatility?

IMNM's at-the-money implied volatility is about 72% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in